A
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Gastrointestinal Cancers
- Tumour Sub-type
- Pancreatic cancer
- Tumour stage
- Early
- Combined Agent(s)
- Capecitabine
- Control Arm
- Gemcitabine
- Treatment Setting
- Resected pancreatic ductal adenocarcinoma
- Trial Name
- ESPAC-4
Primary Outcome(s)
- Primary Outcome(s)
- OS
- Form(s)
- Form 1
Outcome Data
- OS Control
- 25.5 months
- OS Gain
- 2.5 months >10% at five years
- OS HR
- 0.82 (0.68-0.98)
Final Score (after adjustments)
- Final curative score
- A
- Release date
- 15.05.2019
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate